{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:17:37Z","timestamp":1760660257312,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"vor","delay-in-days":3700,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1053\/rmed.2003.1492","type":"journal-article","created":{"date-parts":[[2003,6,2]],"date-time":"2003-06-02T20:33:07Z","timestamp":1054585987000},"page":"625-633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis"],"prefix":"10.1053","volume":"97","author":[{"given":"L.","family":"HAGBERG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"CARBON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.","family":"VAN RENSBURG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"FOGARTY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"DUNBAR","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"PULLMAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/rmed.2003.1492_RF1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/313954","article-title":"Practice guidelines for the management of community-acquired pneumonia in adults","volume":"31","author":"Bartlett","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1053\/rmed.2003.1492_RF2","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/archinte.1997.00440360129015","article-title":"Incidence of community-acquired pneumonia requiring hospitalization","volume":"157","author":"Marston","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1053\/rmed.2003.1492_RF3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0272-5231(05)70237-9","article-title":"Severe community-acquired pneumonia","volume":"20","author":"Ewig","year":"1999","journal-title":"Clin Chest Med"},{"key":"10.1053\/rmed.2003.1492_RF4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thorax.56.1.1","volume":"56","year":"2001","journal-title":"Thorax"},{"key":"10.1053\/rmed.2003.1492_RF5","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1378\/chest.115.suppl_1.9S","article-title":"Treatment of community-acquired pneumonia\u2014IDSA guidelines","volume":"3","author":"Bernstein","year":"1999","journal-title":"Chest"},{"key":"10.1053\/rmed.2003.1492_RF6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00019048-199906000-00003","article-title":"Community-acquired pneumonia due to atypical organisms in adults: diagnosis and treatment","volume":"8","author":"Hammerschlag","year":"1999","journal-title":"Infect Dis Clin Pract"},{"key":"10.1053\/rmed.2003.1492_RF7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00005792-199009000-00004","article-title":"New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases","volume":"69","author":"Fang","year":"1990","journal-title":"Medicine"},{"key":"10.1053\/rmed.2003.1492_RF8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jama.1996.03530260048030","article-title":"Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis","volume":"275","author":"Fine","year":"1996","journal-title":"JAMA"},{"key":"10.1053\/rmed.2003.1492_RF9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0891-5520(05)70207-5","article-title":"Community-acquired pneumonia: epidemiology, etiology, treatment","volume":"12","author":"Marrie","year":"1998","journal-title":"Infect Dis Clin North Am"},{"key":"10.1053\/rmed.2003.1492_RF10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00005792-200103000-00001","article-title":"Community-acquired pneumonia. A prospective outpatient study","volume":"80","author":"Bochud","year":"2001","journal-title":"Medicine"},{"key":"10.1053\/rmed.2003.1492_RF11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJM199701233360402","article-title":"A prediction rule to identify low-risk patients with community-acquired pneumonia","volume":"336","author":"Fine","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/rmed.2003.1492_RF12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1378\/chest.120.1.185","article-title":"Clinical evaluation of the management of community-acquired pneumonia by general practitioners in France","volume":"120","author":"Fantin","year":"2001","journal-title":"Chest"},{"key":"10.1053\/rmed.2003.1492_RF13","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/archinte.159.9.970","article-title":"Processes and outcomes of care for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team (PORT) Cohort Study","volume":"159","author":"Fine","year":"1999","journal-title":"Arch Int Med"},{"key":"10.1053\/rmed.2003.1492_RF14","first-page":"263","article-title":"Telithromycin is highly active against clinical isolates of Streptococcus pneumoniae collected in the PROTEKT study, irrespective of penicillin, macrolide or fluoroquinolone resistance","volume":"7","author":"Felmingham","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1053\/rmed.2003.1492_RF15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/mdr.1999.5.31","article-title":"Penicillin-resistant pneumococci in southern Sweden, 1993\u20131997","volume":"5","author":"Kamme","year":"1999","journal-title":"Microb Drug Resist"},{"key":"10.1053\/rmed.2003.1492_RF16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jac\/45.2.191","article-title":"The Alexander Project 1996\u20131997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections","volume":"45","author":"Felmingham","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/rmed.2003.1492_RF17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","article-title":"Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada","volume":"341","author":"Chen","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/rmed.2003.1492_RF18","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1128\/AAC.43.8.1901","article-title":"Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study","volume":"43","author":"Jacobs","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/rmed.2003.1492_RF19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0732-8893(97)00195-8","article-title":"Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in the 1996\u20131997 respiratory season","volume":"29","author":"Thornsberry","year":"1997","journal-title":"Diagn Microbiol Infect Dis"},{"article-title":"Molecular characterisation of fluoroquinolone-resistant Streptococcus pneumoniae PROTEKT 2000 isolates from Hong Kong [abstract 703]","year":"2001","author":"Morrisey","key":"10.1053\/rmed.2003.1492_RF20"},{"key":"10.1053\/rmed.2003.1492_RF21","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/jac\/46.5.767","article-title":"Streptococcus pneumoniae resistance to macrolide and \u03b2-lactam consumption in Spain (1979\u20131997)","volume":"46","author":"Granizo","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/rmed.2003.1492_RF22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1179\/joc.1999.11.Supplement-2.35","article-title":"Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption","volume":"11","author":"Baquero","year":"1999","journal-title":"J Chemother"},{"key":"10.1053\/rmed.2003.1492_RF23","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1001\/jama.286.15.1857","article-title":"Macrolide resistance among invasive Streptococcus pneumoniae isolates","volume":"286","author":"Hyde","year":"2001","journal-title":"JAMA"},{"key":"10.1053\/rmed.2003.1492_RF24","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0002-9343(99)00104-7","article-title":"Therapy for pneumococcal infection at the millennium: doubts and certainties","volume":"107","author":"Ball","year":"1999","journal-title":"Am J Med"},{"key":"10.1053\/rmed.2003.1492_RF25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0924-8579(01)00394-6","article-title":"The clinical impact of macrolide resistance in pneumococcal respiratory infections","volume":"18","author":"Garau","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1053\/rmed.2003.1492_RF26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1086\/313716","article-title":"Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia","volume":"30","author":"Metlay","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1053\/rmed.2003.1492_RF27","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1086\/318157","article-title":"Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin","volume":"31","author":"Kelley","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1053\/rmed.2003.1492_RF28","first-page":"158","article-title":"Acid stability of new macrolides","volume":"5","author":"Bryskier","year":"1993","journal-title":"J Chemother"},{"key":"10.1053\/rmed.2003.1492_RF29","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1128\/AAC.42.6.1392","article-title":"A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin","volume":"42","author":"Rosato","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/rmed.2003.1492_RF30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/40.1.85","article-title":"Ketolides lack inducibility properties of MLS(B) resistance phenotype","volume":"40","author":"Bonnefoy","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/rmed.2003.1492_RF31","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1365-2958.1999.01202.x","article-title":"The macrolide\u2013ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA","volume":"31","author":"Hansen","year":"1999","journal-title":"Mol Microbiol"},{"key":"10.1053\/rmed.2003.1492_RF32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s002849900403","article-title":"Inhibition of translation and 50S ribosomal subunit formation in S taphylococcus aureus cells by 11 different ketolide antibiotics","volume":"37","author":"Champney","year":"1998","journal-title":"Curr Microbiol"},{"key":"10.1053\/rmed.2003.1492_RF33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2958.2000.01841.x","article-title":"Macrolide\u2013ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA","volume":"36","author":"Douthwaite","year":"2000","journal-title":"Mol Microbiol"},{"key":"10.1053\/rmed.2003.1492_RF34","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/AAC.46.6.1629-1633.2002","article-title":"Activity of the ketolide telithromycin is refractory to erm monomethylation of bacterial rRNA","volume":"46","author":"Liu","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/rmed.2003.1492_RF35","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1365-2958.1999.01203.x","article-title":"A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to peptidyl transferase centre","volume":"31","author":"Xiong","year":"1999","journal-title":"Mol Microbiol"},{"key":"10.1053\/rmed.2003.1492_RF36","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00003495-200161060-00016","article-title":"Telithromycin","volume":"61","author":"Barman Balfour","year":"2001","journal-title":"Drugs"},{"key":"10.1053\/rmed.2003.1492_RF37","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1128\/AAC.42.3.624","article-title":"Susceptibilites of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with other susceptibities to 17 other agents","volume":"42","author":"Pankuch","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/rmed.2003.1492_RF38","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0732-8893(98)00022-4","article-title":"Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains","volume":"31","author":"Biedenbach","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1053\/rmed.2003.1492_RF39","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1128\/AAC.44.7.1980-1982.2000","article-title":"Comparative activities of telithromycin (HMR 3647), levofloxacin and other antimicrobial agents against human mycoplasmas","volume":"44","author":"B\u00e9b\u00e9ar","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/rmed.2003.1492_RF40","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1128\/AAC.42.6.1515","article-title":"In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae","volume":"42","author":"Roblin","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/rmed.2003.1492_RF41","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1128\/AAC.42.6.1520","article-title":"Susceptibilities of Legionella spp. to newer antimicrobials in vitro","volume":"42","author":"Sch\u00fclin","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/rmed.2003.1492_RF42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jac\/48.suppl_2.33","article-title":"Activity of the ketolide antimicrobial telithromycin against typical community-acquired respiratory pathogens","volume":"48","author":"Felmingham","year":"2001","journal-title":"J Antimicrobial Chemother"},{"key":"10.1053\/rmed.2003.1492_RF43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jac\/45.2.167","article-title":"Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes andStreptococcus pneumoniae isolates","volume":"45","author":"Descheemaeker","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/rmed.2003.1492_RF44","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1128\/AAC.44.12.3395-3401.2000","article-title":"Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America","volume":"44","author":"Tait-Kamradt","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/rmed.2003.1492_RF45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1128\/AAC.43.1.90","article-title":"In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with L. pneumophila pneumonia","volume":"43","author":"Edelstein","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/rmed.2003.1492_RF46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/48.suppl_2.25","article-title":"Activity of telithromycin, a new ketolide antimicrobial, against atypical and intracellular respiratory tract pathogens","volume":"48","author":"Hammerschlag","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/rmed.2003.1492_RF47","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/AAC.44.2.414-417.2000","article-title":"Invitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcuspneumoniae","volume":"44","author":"Davies","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/rmed.2003.1492_RF48","unstructured":"Mauvais, P, Bonnefoy, A, Lack of in vitro MLSB resistance induction by the ketolide telithromycin (HMR 3647): role of the 3-keto group [Poster no. 02.10], 2000"},{"key":"10.1053\/rmed.2003.1492_RF49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1469-0691.2001.0070s3024.x","article-title":"Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin","volume":"7","author":"Drusano","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1053\/rmed.2003.1492_RF50","first-page":"36","article-title":"Pharmacodynamics of telithromycin (TEL) in the treatment of community-acquired pneumonia (CAP) [abstract 2186]","author":"Drusano","year":"2001","journal-title":"Abstracts of the 41st Interscience Conference on Antimicro-bial Agents and Chemotherapy"},{"key":"10.1053\/rmed.2003.1492_RF51","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1128\/AAC.45.11.3104-3108.2001","article-title":"Broncho-pulmonary disposition of the ketolide antimicrobial, telithromycin (HMR 3647)","volume":"45","author":"Muller-Serieys","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/rmed.2003.1492_RF52","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jac\/47.6.837","article-title":"Lung concentrations in telithromycin after oral dosing","volume":"47","author":"Khair","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/rmed.2003.1492_RF53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/25.suppl_A.73","article-title":"The pharmacokinetics of azithromycin in human serum and tissues","volume":"25","author":"Foulds","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/rmed.2003.1492_RF54","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/AAC.45.1.170-175.2001","article-title":"Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses","volume":"45","author":"Namour","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/rmed.2003.1492_RF55","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s15010-002-2096-z","article-title":"Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia","volume":"30","author":"Hagberg","year":"2002","journal-title":"Infection"},{"key":"10.1053\/rmed.2003.1492_RF56","first-page":"471","article-title":"Oral telithromycin (HMR 3647: 800mg od) is well tolerated and as effective as oral clarithromycin (500mg bid) in community-acquired pneumonia (CAP) in adults [abstract 2227]","author":"Tellier","year":"2000","journal-title":"Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"10.1053\/rmed.2003.1492_RF57","first-page":"472","article-title":"Oral telithromycin (HMR 3647) 800mg once daily for 7\u201310 days is well tolerated and as effective as oral trovafloxacin 200mg once daily for 7\u201310 days in community-acquired pneumonia [abstract 2230]","author":"Pullman","year":"2000","journal-title":"Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"article-title":"Telithromycin (HMR 3647), a new once-daily ketolide antimicrobial, provides effective treatment of community-acquired pneumonia [Abstract 2245]","year":"2000","author":"Carbon","key":"10.1053\/rmed.2003.1492_RF58"},{"key":"10.1053\/rmed.2003.1492_RF59","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1185\/030079902125001191","article-title":"Efficacy and safety of telithromycin in community-acquired pneumonia","volume":"18","author":"van Rensburg","year":"2002","journal-title":"Current Medical Research and Opinion"},{"article-title":"Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of adult patients with community-acquired pneumonia caused by Streptococcus pneumoniae [abstract 857]","year":"2001","author":"Fogarty","key":"10.1053\/rmed.2003.1492_RF60"},{"key":"10.1053\/rmed.2003.1492_RF61","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia","volume":"163","author":"Niederman","year":"2001","journal-title":"Am J Crit Care Med"},{"key":"10.1053\/rmed.2003.1492_RF62","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archinte.160.10.1399","article-title":"Management of community-acquired pneumonia in the era of pneumococcal resistance","volume":"160","author":"Heffelfinger","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1053\/rmed.2003.1492_RF63","first-page":"783","article-title":"Adult community-acquired staphylococcal pneumonia in the antibiotic era: a review of 61cases","volume":"64","author":"Woodhead","year":"1987","journal-title":"Q J Med"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611103914922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611103914922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:03:31Z","timestamp":1760609011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611103914922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["S0954611103914922"],"URL":"https:\/\/doi.org\/10.1053\/rmed.2003.1492","relation":{},"ISSN":["0954-6111"],"issn-type":[{"type":"print","value":"0954-6111"}],"subject":[],"published":{"date-parts":[[2003,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/rmed.2003.1492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Elsevier Science Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}